Wednesday, January 5, 2011

XMRV drug trials cannot begin soon enough

Annette Whittemore, President, Whittemore Peterson Institute:

when a pathogen such as XMRV is found in over 80% of those tested with the same diagnosis, causality is clearly a reasonable hypothesis that begs further scientific and medical research. It is a known fact that important questions of causality can often be answered through well designed clinical trials.

For those who have suffered for years from these debilitating diseases, novel drug trials cannot begin soon enough.

Read more>>

No comments:


Related Posts with Thumbnails